Exact Sciences Corporation
EXAS
Rang in aandelen
#1153
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Aandeelprijs
$104.91
Laatst gesynchroniseerd: 2026-03-23
Marktkapitalisatie
$20.03B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
71.34%
Land
US
Handel Exact Sciences Corporation (EXAS)
Categorie
Healthcare
Operationele marge voor Exact Sciences Corporation (EXAS)
Operationele marge op October 2026 TTM: -4.11%
Volgens de meest recente financiële rapporten en aandelenkoers van Exact Sciences Corporation is de huidige operationele marge (TTM) -4.11%. Eind 2023 had het bedrijf een operationele marge van -8.60%.
Geschiedenis van de operationele marge van Exact Sciences Corporation van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | -4.11% | -89.19% |
| 2024 | -38.01% | 341.98% |
| 2023 | -8.60% | -68.96% |
| 2022 | -27.71% | -41.39% |
| 2021 | -47.28% | 26.28% |
| 2020 | -37.44% | 40.33% |
| 2019 | -26.68% | -23.97% |
| 2018 | -35.09% | -21.11% |
| 2017 | -44.48% | -73.85% |
| 2016 | -170.08% | -57.83% |
| 2015 | -403.35% | -92.79% |
| 2014 | -5,591.71% | 395.54% |
| 2013 | -1,128.40% | -11.17% |
| 2012 | -1,270.32% | 83.48% |
| 2011 | -692.36% | 212.87% |
| 2010 | -221.29% | 14.34% |
| 2009 | -193.53% | -116.82% |
| 2008 | 1,150.29% | -362.79% |
| 2007 | -437.72% | 46.76% |
| 2006 | -298.25% | -18.92% |
| 2005 | -367.86% | -5.42% |
| 2004 | -388.96% | -60.87% |
| 2003 | -994.07% | -71.09% |
| 2002 | -3,438.68% | -93.31% |
| 2001 | -51,406.44% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 17.97% | -104.37% |
US
|
|
| 20.42% | -104.97% |
US
|
|
| -10.70% | -97.40% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -105.41% |
US
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.